See more : China Railway Group Limited (0390.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectar Biosciences, Inc. (CLRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectar Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Minor International PCL (8MI.SG) Income Statement Analysis – Financial Results
- Ekter SA (EKTER.AT) Income Statement Analysis – Financial Results
- RICECURRY INC (195A.T) Income Statement Analysis – Financial Results
- Bradespar S.A. (BRAP3.SA) Income Statement Analysis – Financial Results
- Spotify Technology S.A. (SPOT) Income Statement Analysis – Financial Results
Cellectar Biosciences, Inc. (CLRB)
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 4.96K |
| Cost of Revenue | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K |
| Gross Profit | -192.38K | -238.87K | -227.64K | -207.93K | -189.36K | -82.27K | -1.55M | -356.67K | -362.50K | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 2.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 48.85% |
| Research & Development | 27.27M | 19.22M | 17.59M | 10.14M | 9.00M | 6.84M | 9.47M | 4.75M | 5.16M | 5.96M | 6.86M | 5.12M | 3.60M | 3.00M | 8.08M | 14.53M | 17.43M | 6.44M | 1.14M | 261.77K |
| General & Administrative | 10.75M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 0.00 | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 0.00 | 0.00 |
| Selling & Marketing | 945.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.69M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 2.69M | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 1.44M | 365.88K |
| Other Expenses | 0.00 | 0.00 | 6.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 627.64K |
| Cost & Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 630.18K |
| Interest Income | 0.00 | 152.52K | 2.28K | 10.90K | 42.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 4.50K | 2.42K | 1.01K | 130.61K | 729.92K | 637.75K | 49.88K | 95.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.69K | 16.61K | 7.90K | 841.00 | 446.31K | 9.35K | 9.34K | 430.02K | 2.42K | 1.01K | 130.61K | 0.00 | 0.00 | 0.00 | 208.74K |
| Depreciation & Amortization | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 367.20K | 424.76K | 497.25K | 584.84K | 35.34K | 32.35K | 16.89K | 15.37K | 9.52K | 3.24K | 2.54K |
| EBITDA | -38.77M | -28.67M | -23.98M | -15.15M | -13.90M | -13.16M | -12.05M | -9.09M | -8.19M | -9.30M | -10.88M | -8.29M | -6.33M | -12.96M | -10.17M | -16.59M | -19.54M | -8.28M | -2.94M | -604.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45,388.96% | -38,876.20% | 2,049.87% | -13,164.56% | 0.00% | 0.00% | -16,968.75% | -12,172.63% |
| Operating Income | -38.96M | -28.81M | -24.13M | -15.29M | -14.18M | -13.33M | -13.60M | -9.45M | -8.76M | -9.89M | -12.40M | -8.75M | -7.04M | -5.45M | -10.17M | -16.59M | -20.29M | -8.93M | -5.09M | -625.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 63,979.27% | -16,351.72% | -10,555.25% | -13,170.82% | 0.00% | 0.00% | -40,428.32% | -12,600.14% |
| Total Other Income/Expenses | 917.15K | 152.52K | 8.92K | 196.18K | 85.71K | 91.74K | 38.68K | 3.27M | 3.26M | 1.78M | 522.76K | -42.19K | -1.89M | -7.20M | -12.11M | 139.61K | 737.05K | 382.63K | -487.02K | -190.07K |
| Income Before Tax | -38.04M | -28.66M | -24.12M | -15.09M | -14.09M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.75M | -12.65M | -26.28M | -22.96M | -29.72M | -8.55M | -3.16M | -815.29K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 70,469.15% | -37,960.15% | -27,289.52% | -18,227.50% | 0.00% | 0.00% | -25,146.86% | -16,430.57% |
| Income Tax Expense | -60.00K | -60.00K | -152.20K | -337.63K | -218.51K | -1.55M | -38.68K | -3.27M | -3.42M | -1.56M | -522.76K | 9.34K | 1.14M | -7.55M | 12.11M | -139.61K | -737.05K | -643.75K | 487.02K | 0.00 |
| Net Income | -37.98M | -28.60M | -23.97M | -14.76M | -13.87M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.44M | 2.10M | -22.27M | -16.45M | -19.56M | -8.29M | -3.05M | -815.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 67,594.75% | 6,286.05% | -23,125.72% | -13,059.99% | 0.00% | 0.00% | -24,264.14% | -16,430.57% |
| EPS | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| EPS Diluted | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| Weighted Avg Shares Out | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
| Weighted Avg Shares Out (Dil) | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar's chief...
Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical...
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical...
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its...
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia
The EMA's PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options The EMA's PRIME status is granted to drug candidates that may offer a major therapeutic...
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that it has closed on...
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30,...
Here's Why Cellectar Biosciences Shares Are Rising
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Source: https://incomestatements.info
Category: Stock Reports